Streamlining Discovery and Development Workflows Using Engineered P. fluorescens Strains for ncAA Incorporation and Extracellular Protein Production
Diane Retallack, President & COO, Primrose Bio at PEGS Boston Summit 2026
Streamlined product discovery and development workflows are critical to facilitate efficient decision making and candidate advancement. Improvements in extracellular (EC) localization and ncAA incorporation within the Pfenex platform can accelerate discovery and development timelines. Engineered host strains show EC production of a wide range of proteins, enabling streamlined recovery and analysis. Further, high fidelity, high titer production of target proteins with 100% ncAA incorporation has been established, with titers up to 15g/L in fermentation.
Diane Retallack
President & COO
Diane Retallack, PhD was a founding member of the team that established the Pfenex Expression Technology® platform, overseeing strain engineering, HTP screening, and upstream development. With over 25 years of experience in molecular biology, protein expression, and executive management, she has contributed to multiple therapeutic programs from product conception through commercialization. Diane completed her doctorate at the University of Michigan and post-doctoral work at the University of Wisconsin-Madison.
Ready to Discuss Your Program?
Book a Time With Our Team
Questions about this presentation
Who presented this work and where?
Diane Retallack, PhD, President and COO of Primrose Bio, at the PEGS Boston Summit 2026.
What titers were achieved with ncAA incorporation?
High fidelity, high titer production of target proteins with 100% ncAA incorporation has been established, with titers up to 15 g/L in fermentation.
What does extracellular production enable?
Engineered host strains show extracellular production of a wide range of proteins, which enables streamlined recovery and analysis and shortens discovery and development timelines.